Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BEPOTASTINE BESILATE vs ADVIL COLD AND SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
Allergic conjunctivitis (FDA approved),Allergic rhinitis (off-label),Urticaria (off-label)
Temporary relief of sinus congestion and pressure,Temporary relief of nasal congestion,Temporary reduction of fever,Relief of minor aches and pains associated with the common cold or flu
2 mg/m L ophthalmic solution: 1 drop in each affected eye twice daily.
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.
Terminal elimination half-life is approximately 9-10 hours in healthy adults, allowing twice-daily dosing for allergic conjunctivitis.
Ibuprofen: 2-4 hours (terminal; rapid elimination, no accumulation with intermittent use). Pseudoephedrine: 4-8 hours (terminal; prolonged in alkaline urine, up to 16 hours at p H 8).
Primarily metabolized via glucuronidation (UGT1A9, UGT2B7) and oxidation (CYP3A4 minor pathway).
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
Primarily renal excretion as unchanged drug (~75-80% of dose) with minor fecal elimination (~10-15%).
Renal excretion of unchanged drug and metabolites: ibuprofen ~45-60% (primarily as conjugated metabolites, <10% unchanged), pseudoephedrine ~70-90% unchanged. Biliary/fecal elimination accounts for <10% for both components.
Approximately 55-60% bound to human plasma proteins, primarily albumin.
Ibuprofen: ~99% primarily to albumin. Pseudoephedrine: negligible (<10% bound to plasma proteins).
Following oral administration, Vd is 1.4-1.8 L/kg, indicating extensive tissue distribution. Not applicable for ophthalmic use.
Ibuprofen: 0.1-0.2 L/kg (low Vd, indicating limited tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (high Vd, extensive tissue distribution including CNS).
Oral bioavailability is <1% due to extensive first-pass metabolism. Ophthalmic: Systemic absorption negligible (<0.5%).
Oral: ibuprofen ~80-100% (rapidly absorbed, no significant first-pass). Pseudoephedrine ~100% (well absorbed, minimal first-pass metabolism).
No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min).
GFR 30-89 m L/min: Use lowest effective dose for shortest duration; monitor renal function. GFR <30 m L/min or dialysis: Contraindicated.
No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Child-Pugh Class A: No adjustment; use with caution. Child-Pugh Class B or C: Avoid use.
≥2 years: same as adult dose (1 drop in each affected eye twice daily).
Children <12 years: Do not use. Children ≥12 years: Same as adult dosing; 1-2 tablets every 4-6 hours as needed; maximum 6 tablets in 24 hours.
No dose adjustment required; same as adult dosing.
Use lowest effective dose for shortest duration; avoid chronic use. Reduce initial dose to 1 tablet every 6-8 hours due to increased risk of renal impairment, GI bleeding, and cardiovascular events.
None.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
May cause severe hypersensitivity reactions (angioedema, bronchospasm).,Avoid use in patients with known hypersensitivity to bepotastine.,Ophthalmic use: do not wear contact lenses during treatment; may cause transient burning/stinging.,Systemic use: caution in patients with renal impairment (dose adjustment required).,Avoid concurrent use with CNS depressants due to additive sedative effects.
Cardiovascular thrombotic events, gastrointestinal bleeding/ulceration/perforation, hypertension, renal toxicity, serious skin reactions, anaphylactoid reactions, exacerbation of asthma, and drug interactions including with ACE inhibitors, diuretics, and lithium.
Hypersensitivity to bepotastine or any component of the formulation.,Severe renal impairment (Cr Cl <30 m L/min) for systemic use.
Hypersensitivity to ibuprofen, aspirin, or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; patients with severe hypertension or coronary artery disease; patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs; concurrent use of other sympathomimetics; in the setting of CABG surgery.
No clinically significant food interactions reported with ophthalmic use.
Take with food or milk to reduce gastrointestinal irritation. Avoid alcohol consumption as it increases the risk of NSAID-related gastric ulcers and bleeding. High-sodium foods may exacerbate hypertension in patients sensitive to the pressor effects of pseudoephedrine.
Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human clinical dose) and 100 mg/kg/day in rabbits (approximately 200 times the human clinical dose), but there are no adequate and well-controlled studies in pregnant women. During the first trimester, the risk is unknown; during the second and third trimesters, potential risks to the fetus cannot be excluded.
First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.62) for any malformation and 1.86 (95% CI 1.32-2.62) for cardiac malformations. Second trimester: Risk of oligohydramnios and premature closure of ductus arteriosus after 20 weeks. Third trimester: Avoid after 30 weeks due to risk of premature ductus arteriosus closure and oligohydramnios; after 32 weeks, increased risk of necrotizing enterocolitis, intracranial hemorrhage, and renal impairment in neonate (renal agenesis/dysgenesis). Pseudoephedrine: First trimester – possible increased risk of gastroschisis (odds ratio 1.8, 95% CI 1.0-3.2) and small intestinal atresia. Second and third trimesters: potential uteroplacental vasoconstriction leading to fetal hypoxia; risk of prematurity and low birth weight.
It is not known whether bepotastine besilate is excreted in human milk. In rat studies, drug-related material was detected in milk following oral administration. Because many drugs are excreted in human milk, caution should be exercised when bepotastine besilate is administered to a nursing woman. The milk-to-plasma (M/P) ratio has not been established for humans. Breastfeeding is not recommended during treatment.
Ibuprofen: M/P ratio 0.005–0.006; low transfer into breast milk; AAP compatible; theoretical risk of platelet dysfunction in neonate. Pseudoephedrine: M/P ratio 2.6–3.5 (concentrated in milk); estimated infant dose 4.3% of maternal weight-adjusted dose; may cause irritability and sleep disturbances in infant; may reduce milk production by up to 24%. Caution advised; avoid in lactation if possible.
No dose adjustments are recommended for pregnant women based on current pharmacokinetic data. However, systemic absorption after ophthalmic administration is minimal, and no pregnancy-specific pharmacokinetic studies have been conducted. Use caution and prescribe only if clearly needed.
Ibuprofen: No dose adjustment required; however, use lowest effective dose and shortest duration; avoid after 30 weeks gestation. Pseudoephedrine: No specific dose adjustment recommended based on pharmacokinetic changes, but use with caution due to vasoconstrictive effects; reduced efficacy may be observed due to increased plasma volume and renal clearance.
Bepotastine besilate is a selective histamine H1 receptor antagonist used topically for allergic conjunctivitis. Avoid use with contact lenses; remove before instillation and wait at least 10 minutes before reinserting. Systemic absorption is minimal, but caution in patients with severe hepatic impairment. Onset of action is within 15 minutes, duration 8 hours. Do not touch dropper tip to eye or surrounding surfaces.
Advil Cold and Sinus is a fixed-dose combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen inhibits COX-1/2, reducing prostaglandin synthesis, while pseudoephedrine is an α-adrenergic agonist causing vasoconstriction in nasal mucosa. Use cautiously in patients with hypertension, cardiovascular disease, or renal impairment due to pseudoephedrine's pressor effects and ibuprofen's potential to reduce renal blood flow and antagonize antihypertensives. Avoid in patients with severe coronary artery disease, uncontrolled hypertension, or concurrent MAOI use. Max duration: 3 days for sinus symptoms, 5 days for pain. Monitor for NSAID-induced GI bleeding, especially in elderly or those on anticoagulants/aspirin.
Wash hands before use.,Tilt head back, pull lower eyelid down, and instill one drop in the affected eye(s) twice daily.,Do not touch the dropper tip to your eye or any surface.,Remove contact lenses before use and wait at least 10 minutes before reinserting.,Do not use if solution changes color or becomes cloudy.,Common side effects include mild eye irritation, bitter taste, or headache.,If you experience eye pain, vision changes, or redness, contact your doctor.
Do not take more than directed; do not exceed 6 caplets in 24 hours.,Avoid use with other products containing ibuprofen or other NSAIDs, including aspirin, to prevent overdose and serious side effects.,Discontinue use and seek medical attention if symptoms worsen, persist >3 days for sinus or >5 days for pain, or if new symptoms occur.,Take with food or milk to reduce stomach upset; avoid alcohol to lower risk of GI bleeding.,If you have high blood pressure, heart disease, thyroid disease, diabetes, or difficulty urinating due to prostate enlargement, consult a doctor before use.,Do not use if you are taking a prescription monoamine oxidase inhibitor (MAOI) or for 2 weeks after stopping an MAOI drug.,Pregnant or breastfeeding women should not use this product; ibuprofen is contraindicated in third trimester due to risk of premature closure of ductus arteriosus.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BEPOTASTINE BESILATE vs ADVIL COLD AND SINUS, answered by our medical review team.
BEPOTASTINE BESILATE is a Ophthalmic Antihistamine that works by Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.. ADVIL COLD AND SINUS is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BEPOTASTINE BESILATE and ADVIL COLD AND SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BEPOTASTINE BESILATE is: 2 mg/m L ophthalmic solution: 1 drop in each affected eye twice daily.. The standard adult dose of ADVIL COLD AND SINUS is: 1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BEPOTASTINE BESILATE and ADVIL COLD AND SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BEPOTASTINE BESILATE is classified as Category C. Bepotastine besilate is not recommended during pregnancy. Animal studies have shown no teratogenic effects at doses up to 200 mg/kg/day in rats (approximately 200 times the human c. ADVIL COLD AND SINUS is classified as Category C. First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.